ReviewCureus2024
Pregabalin for the Treatment of Neuropathic Pain: A Systematic Review of Patient-Reported Outcomes.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain (NeP) arises from pathologies of the nervous system, significantly impacting patient functionality and quality of life. Pregabalin is a first-line treatment for NeP, but there has been limited focus on patient-reported outcomes (PROs). This systematic review synthesizes PROs from clinical studies assessing pregabalin's efficacy in treating NeP, with a focus on sleep disturbance, mental health, and health-related quality of life (HRQOL). Following Cochrane Collaboration guidelines, we conducted a systematic search of randomized controlled trials and epidemiological studies reporting PROs associated with pregabalin treatment for NeP. Sixteen studies met the inclusion criteria and were narratively synthesized. The findings indicate that pregabalin significantly improved sleep interference and HRQOL across multiple studies, particularly at doses of 300 mg/day or higher. However, improvements in mental health outcomes, such as anxiety and depression, were inconsistent across studies. No meta-analysis was conducted due to the heterogeneity of outcomes. In conclusion, while pregabalin shows robust efficacy in reducing NeP-related sleep disturbances, its effects on mental health and HRQOL are less consistent. These findings highlight the need for a more holistic approach to NeP treatment, incorporating both clinical outcomes and PROs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.